Time filter

Source Type

Suita, Japan

Sasada S.,Depf. of Surgery | Ukon K.,Depf. of Surgery | Sato Y.,Depf. of Surgery
Japanese Journal of Cancer and Chemotherapy

A 60-year-old woman underwent a low anterior resection advanced rectal adenocarcinoma (Stage III a). Despite adjuvant therapy, liver metastasis and local recurrence appeared. Chemotherapy and radiotherapy were performed, nevertheless, the medical condition progressed, and pain with defecation by local recurrence appeared. The pain became resistant to the treatment due to non-opioid and opioid analgesics, and her quality of life (QOL) was gradually reduced. Transverse colostomy was performed as a palliative surgery to eliminate any contact stimulations during defecation. After surgery, pain improved, analgesics were no longer needed, and anti-cancer therapy was resumed. Palliative surgery should be considered for cancer pain resistant to drug therapy, if the trigger factors of pain can be expected to be removed. Source

Yanagawa T.,Depf. of Surgery | Shimizu J.,Depf. of Surgery | Dono K.,Depf. of Surgery | Yasumoto T.,Toyonaka Municipal Hospital | And 15 more authors.
Japanese Journal of Cancer and Chemotherapy

A 75-year-old female presented with appetite and weight loss and epigastralgia. CT revealed a primary gallbladder carcinoma Stage IVb with multiple hepatic metastases. Gastrofiberscopy revealed an invasion to duodenal and bleeding from the tumor. For her poor performance status, it seems to be too difficult to undergo a general chemotherapy. So after gastrojejunostomy, transarterial embolization (TAE) was performed. She underwent 2 times TAE. There was a notable reduction in tumor size. But pulmonary metastases were found in bilateral lung. She died after 8 months. TAE may be useful for advanced gallbladder carcinoma with tumor vascularity. Source

Tono T.,Depf. of Surgery | Kim C.,Depf. of Surgery | Kanoh T.,Depf. of Surgery | Ohnishi T.,Depf. of Surgery | And 12 more authors.
Japanese Journal of Cancer and Chemotherapy

The authors analyzed the 62 patients who underwent hepatic arterial infusion (HAI) chemotherapy using W-spiral (WS) catheter. The catheter was successfully inserted into the hepatic artery without a coil fixation in 57 cases. After cessation of chemotherapy, the catheter was removed in 32 cases without difficulty, which resulted in improved patients' quality of life as well as preservation of patency of hepatic arteries. This catheter has a special shape-memory alloy in its tip, which allows preferable fixation without coils and removal of the catheter if desired. HAI using this catheter and subsequent removal of it is a reasonable strategy in the era with potent systemic chemotherapy. Source

Ota H.,Depf. of Surgery | Nagano H.,Osaka University | Murakami M.,Depf. of Surgery | Nagase H.,Depf. of Surgery | And 7 more authors.
Japanese Journal of Cancer and Chemotherapy

A patient was a 61-year-old male. In December 2005, abdominal computer tomography (CT) revealed at a 4cm-in-diameter early enhanced lesion in S6 and a 1.5cm-in-diameter early enhanced lesion in S5/8, which were diagnosed as hepatocellular carcinomas. He underwent S6 partial hepatectomy and S5/8 partial hepatectomy. However, multiple lung metastatic lesions and a peritoneal metastatic lesion were detected by computer tomography (CT) in July 2007, led to a diagnosis as recurrence of HCC. Although he received S-1 /IFN-a combination systemic chemotherapy, no effect was shown and peritoneal metastatic lesion grew to 10cm-in-diameter. We thought that this lesion might lead to ileus, therefore, he received peritoneal tumor resection in December 2007. Multiple lung metastases grew and he was dead 13 months after the surgery: no abdominal symptom and sign due to ileus was noted. In this case, it was considered that a resection of peritoneal metastasis might be attempted to prevent ileus, even if there were other metastatic lesions, such as multiple lung metastases. Source

Kubota O.,Depf. of Surgery | Onuki Y.,Depf. of Surgery | Uchiyama T.,Depf. of Surgery | Oishi K.,Depf. of Surgery | Takeda M.,Depf. of Surgery
Japanese Journal of Cancer and Chemotherapy

Background: Aromatase inhibitors (Als) are frequently employed for advanced or metastatic postmenopausal breast cancer as first-line hormone therapy. However, it is unknown which hormonal agent is the most appropriate after Al has failed. Patients and Methods: Five hormone-responsive postmenopausal women who used Al as a first-line hormone therapy for advanced or metastatic breast cancer, but Al failed, received high-dose toremifene therapy (HD-TOR: 120mg/day) in our hospital. Efficacy and safety were evaluated. Results: Patients were all-hormone sensitive, and only one case had HER2 overexpression. All patients had received anastrozole (ANA) as first-line hormone therapy. Of a total of 5 cases, 3 were evaluated as partial responses (PR), 1 was a long stable disease (L-SD), and 1 was a progressive disease (PD). The overall response rate (RR) was 60. 0% (3/5 cases) and the clinical benefit rate (CB) was 80.0% (4/5 cases). Grade 1 dry mouth was observed in one case as an adverse event. Conclusions: HD-TOR as a second-line therapy is optimal for advanced or metastatic Al resistance postmenopausal breast cancer. Source

Discover hidden collaborations